Business Context and Reporting Period
This Form 8-K, dated March 15, 2020, reports that AcelRx Pharmaceuticals, Inc. ("AcelRx") entered into a definitive Merger Agreement to acquire Tetraphase Pharmaceuticals, Inc. ("Tetraphase"). Under the agreement, a wholly-owned subsidiary of AcelRx will merge with Tetraphase, with Tetraphase surviving as an indirect subsidiary of AcelRx. The filing also discloses the execution of a Co-Promotion Agreement between the two companies.
Key Financial Metrics and Transaction Terms
The filing details the financial structure of the merger rather than historical operating results. Key terms include:
- Exchange Ratio: Tetraphase shareholders will receive 0.6303 shares of AcelRx common stock for each Tetraphase share held.
- Contingent Value Rights (CVRs): Shareholders will receive CVRs entitling them to up to $12.5 million in aggregate contingent consideration based on future annual net sales of the product XERAVA.
- CVR Milestones:
- $2.5 million upon achieving specified sales in 2021.
- $4.5 million upon achieving specified sales in any year ending on or before December 31, 2024.
- $5.5 million upon achieving specified sales in any year ending on or before December 31, 2024.
- Payment Form: AcelRx may pay CVR consideration in cash or stock, subject to a cap where total shares issued (including CVRs) do not exceed 19.9% of AcelRx's pre-merger outstanding shares.
- Termination Fees: Tetraphase must pay $810,000 if it terminates to accept a superior offer. If the merger fails due to stockholder vote rejection, Tetraphase must reimburse AcelRx up to $200,000 in transaction expenses.
Note: The filing text does not provide clear values for AcelRx or Tetraphase's current revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Agreements
The primary material change is the entry into the Merger Agreement and related contracts:
- Co-Promotion Agreement: A five-year agreement for AcelRx and Tetraphase to detail and promote each other's products, overseen by a joint committee. Either party may terminate with 15 months' notice or upon material breach/insolvency.
- Voting Agreements: Stockholders representing approximately 31% of Tetraphase's voting power have agreed to vote in favor of the merger and against alternative proposals.
- Equity Treatment: Tetraphase options will terminate; unvested restricted stock units (RSUs) will vest in full; warrants will be exchanged for AcelRx stock or a percentage of the merger consideration.
Guidance, Outlook, and Risks
Conditions to Closing: The merger is subject to customary conditions, including Tetraphase stockholder approval, SEC effectiveness of the Form S-4 registration statement, and a minimum "Company Net Cash" of $5.0 million at closing. If net cash is below $5.0 million, the exchange ratio will be adjusted.
Risks and Contingencies:
- Forward-Looking Statements: The filing cautions that actual results may differ materially from projections regarding the merger's benefits and cost synergies.
- CVR Uncertainty: There is no assurance that the specified XERAVA sales levels will be achieved, meaning CVR payments may not be made.
- Regulatory and Stockholder Approval: The transaction requires regulatory filings and a majority vote by Tetraphase stockholders.
Investor Verification Checklist
- Verify the final exchange ratio and any adjustments based on the "Company Net Cash" definition in the Merger Agreement.
- Review the specific annual net sales thresholds for XERAVA required to trigger the $12.5 million in CVR payments.
- Monitor the status of the Form S-4 registration statement and the scheduled Tetraphase stockholder special meeting.
- Assess the impact of the 19.9% cap on total AcelRx shares issuable on the potential cash vs. stock payment for CVRs.
- Confirm the terms of the Co-Promotion Agreement regarding the joint marketing committee and termination rights.